Janssen Pharmaceutical Companies announced a worldwide collaboration and license agreement with MeiraGTx Holdings to develop, manufacture and commercialize gene therapy programs for inherited retinal diseases.
According to a Janssen press release, the companies also will explore new targets for inherited retinal diseases and further develop adeno-associated virus manufacturing technology.
The agreement will see Janssen and MeiraGTx develop Janssen’s clinical stage inherited retinal disease portfolio, including product candidates for achromatopsia and X-linked retinitis pigmentosa.
MeiraGTx
Uncategorized